- Home
- FLY vs HALO Comparison
FLY vs HALO Comparison
Compare FLY & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLY
- HALO
- Stock Information
- Founded
- FLY 2017
- HALO 1998
- Country
- FLY United States
- HALO United States
- Employees
- FLY N/A
- HALO N/A
- Industry
- FLY Military/Government/Technical
- HALO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FLY Industrials
- HALO Health Care
- Exchange
- FLY Nasdaq
- HALO Nasdaq
- Market Cap
- FLY 6.4B
- HALO 7.6B
- IPO Year
- FLY 2025
- HALO N/A
- Fundamental
- Price
- FLY $25.05
- HALO $65.26
- Analyst Decision
- FLY Buy
- HALO Buy
- Analyst Count
- FLY 6
- HALO 11
- Target Price
- FLY $55.17
- HALO $73.18
- AVG Volume (30 Days)
- FLY 2.2M
- HALO 1.8M
- Earning Date
- FLY 11-12-2025
- HALO 11-03-2025
- Dividend Yield
- FLY N/A
- HALO N/A
- EPS Growth
- FLY N/A
- HALO 68.93
- EPS
- FLY N/A
- HALO 4.37
- Revenue
- FLY $102,808,000.00
- HALO $1,178,672,000.00
- Revenue This Year
- FLY $125.10
- HALO $32.47
- Revenue Next Year
- FLY $233.49
- HALO $24.01
- P/E Ratio
- FLY N/A
- HALO $14.95
- Revenue Growth
- FLY 10.06
- HALO 34.97
- 52 Week Low
- FLY $24.65
- HALO $42.01
- 52 Week High
- FLY $73.80
- HALO $79.50
- Technical
- Relative Strength Index (RSI)
- FLY N/A
- HALO 36.63
- Support Level
- FLY N/A
- HALO $64.55
- Resistance Level
- FLY N/A
- HALO $67.28
- Average True Range (ATR)
- FLY 0.00
- HALO 1.68
- MACD
- FLY 0.00
- HALO -0.03
- Stochastic Oscillator
- FLY 0.00
- HALO 34.76
About FLY Firefly Aerospace Inc. Common Stock
Firefly Aerospace Inc is a space and defense technology company with an established track record of success providing comprehensive mission solutions to national security, government, and commercial customers. The company enables government and commercial customers to launch, land and operate in space - Anywhere, Anytime.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.